We offer a complete line of in silico and in vitro services for manufacturability, immunogenicity, humanization, and protein engineering. These technologies include our award winning and patented Epibase® T cell epitope screening platform for immunogenicity assessment along with our proprietary technology platform for structural protein engineering. Our Cambridge, UK-based Early development Services scientists will help you determine a testing strategy, analyze and interpret the data, and recommend next steps throughout the process.

In addition to our protein design and optimization services, we also offer a protein production service for mg to g quantities of non-GMP material. Lonza’s Light Path™ programs are streamlined and available for both mammalian and microbial applications.

Lonza’s protein design and optimization services were developed to mitigate risks, reduce attrition, and improve the quality and safety of therapeutic proteins. They also address the challenges and accelerate the design and development of efficacious vaccines. These services provide a complete portfolio for your late discovery and early development needs.

Our early stage services are diverse, include but not limited to:

MAPPS, post translational modification, CDC assays, Humanisation, ADCC assays, Cell proliferations, Cytokine assays, PTM prediction, Humanization, Deimmunization, Aggregation analysis, in silico T cell epitope prediction, B cell assays, T cell activation, T cell assays, Developability assessment, Immunogenicity, Immunogenicity prediction, Manufacturability assessment.